Outpatients / Inpatients With Depression
Conditions
Keywords
Shuganjieyu capsule, depression
Brief summary
This study mainly evaluates the efficacy and safety of Shuganjieyu capsule combined with Fluoxetine as well as the Fluoxetine monotherapy for the treatment of depression in the basic study, and also explores the efficacy for the extended study period as well as the efficacy and safety for the full trial period (basic study period and extended study period).
Detailed description
Whole-course treatment serves as the principle for the treatment of depression, including symptom control in the acute phase, relapse prevention in the consolidation period and recurrence prevention in the maintenance period. Western medicine usually adopts antidepressant drugs combined with psychotherapy, mainly antidepressant SSRI at the current stage. It can selectively inhibit serotonin reuptake, so as to play an antidepressant role, but for somatic symptoms, the effect is general. Based on the overall regulation of body and mind, traditional Chinese medicine aims to achieve individualized treatment combing syndrome differentiation and treatment in a multi-channel, multi-target, and multi-level manner. At present, the combined application of antidepressant chemical drugs and Chinese patent medicines is complementary to each other from the perspective of mechanism and clinical practice. However, the study of Shuganjieyu capsule combined with antidepressant chemical drugs is mostly concentrated in the short term, and the benefits of long-term combined use of Shuganjieyu capsule remain to be further studied. The purpose of this multicenter clinical study is to evaluate the efficacy and safety of Shuganjieyu capsule combined with Fluoxetine as well as the Fluoxetine monotherapy in the basic study period. Besides, the study aims to continue to observe the efficacy and safety in the extended study research period, so as to provide important clinical data for the whole-course medication. Recruitment of outpatients / inpatients with depression. After screening the patients who met the inclusion criteria, the study collected demographic data, recorded symptoms and scale scores and improved relevant laboratory tests. The experimental group was treated with Shuganjieyu capsule combined with Fluoxetine, and the control group was treated with Fluoxetine. The related indexes were evaluated 2 ,4, 8, 12, 16 and 24 weeks later.
Interventions
2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day.
DRUGFluoxetine
Fluoxetine 20 mg, once a day. According to the study progress, the dosage can be adjusted to 40 mg , once per day.
DRUGPlacebo
Shuganjieyu capsule simulator 2 capsules each time, twice a day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day.
Sponsors
Peking University
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. In line with the diagnostic criteria for depression of Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5); 2. Age: 18-65 (including 18 and 65), gender unlimited; 3. Hamilton Rating Scale for Depression (HAMD-17) score≥18 in the screening period, and the 13th score≥2; 4. For women of childbearing age, pregnancy test must be negative and not in lactation. The contraception measure must be accepted by the Investigators. Participants should agree to maintain this measure throughout the whole process; 5. Sign the informed consent form voluntarily and agree to participate in all visits, examinations and treatment as required by the trial protocol.
Exclusion criteria
1. Treatment-resistant depression (patients with poor clinical efficacy of antidepressants with two or more different mechanisms after sufficient and full course of treatment); 2. Patients who meet DSM-5 diagnostic criteria for other mental disorders (such as schizophrenia pedigree and other mental disorders, bipolar and related disorders, anxiety disorders, obsessive-compulsive and related disorders, somatic symptoms and related disorders); 3. Depression caused by psychoactive drugs; 4. Patients with severe suicide (HAMD-17 suicide score≥3) and injury tendency; 5. Patients with serious or unstable cardiovascular, cerebrovascular, liver, kidney, endocrine, digestive and blood diseases; 6. Depressive episodes secondary to other mental diseases or somatic diseases at an active stage; 7. ALT and AST values in the liver function examination are more than double the upper limit of reference value, or Scr value is above the upper limit of reference value; 8. Patients with a history of endocrine diseases such as hyperthyroidism and hypothyroidism who are currently active; 9. Patients who had undergone psychiatric surgery or electroconvulsive therapy in the past three months; 10. Anyone with an allergic constitution known or suspected to have an allergic history to Hypericum perforatum L., Eleutherococcus senticosus and Fluoxetine; 11. Those who have previously failed Shuganjieyu capsule or Fluoxetine treatment; 12. Women in pregnancy or lactation period. Women who plan to get pregnant during the study and within six months; 13. Patients with psychoactive substance abuse or dependence in the past 12 months; 14. Long-term use of caffeine and nicotine; 15. Patients who have received or are receiving any other clinical trial drug treatment within three months before the trial; 16. Patients who are taking drugs that interfere with the efficacy evaluation of the investigational drugs, and drugs that are forbidden to be used in combination with the test drugs. Patients who have received antidepressant drugs for systematical treatment within 4 weeks; 17. Those who are regarded as unsuitable by investigators for this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 17-item Hamilton depression rating scale (HAMD-17) total scores change | Day 0 to Day 56 | The change value of HAMD-17 total scores compared to the baseline (V1) after 8 weeks of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 17-item Hamilton depression rating scale (HAMD-17) total scores change at early time points | Day 0 to Day 14, Day 0 to Day 28 | The change value of HAMD-17 total scores compared to the baseline |
| Hamilton anxiety rating scale (HAMA) total score change | Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56 | The change value of HAMA total scores compared to the baseline |
| Patient Health Questionnaire-15 (PHQ-15) score change | Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56 | The change value of PHQ-15 total scores compared to the baseline |
| Clinical Global Impression (CGI) score change | Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56 | The change value of CGI total scores compared to the baseline |
| Pittsburgh Sleep Quality Index (PSQI) score change | Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56 | The change value of PSQI total scores compared to the baseline |
| Dimensional Anhedonia Rating Scale (DARS) total score change | Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56 | The change value of DARS total scores compared to the baseline |
| Temporal Experience of Pleasure Scale (TEPS) total score change | Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56 | The change value of TEPS total scores compared to the baseline |
| Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) total score change | Day 0 to Day 56 | The change value of Q-LES-Q-SF total scores compared to the baseline |
Countries
China
Outcome results
None listed